Objective To investigate the application of SRS MapCHECK (SRS), ArcCHECK (Arc) and Portal Dosimetry (PD) dose verification systems in the verification of stereotactic treatment plans. Methods A total of 45 tumor patients who received stereotactic radiotherapy in our hospital were analyzed retrospectively, and the verification plans of SRS, Arc and PD were designed according to the treatment plan and executed on the Varian VitalBeam linear accelerator. At the 10% dose threshold, the pass rates of the three dose verification systems under the γ evaluation criteria of 3%/2 mm, 3%/1 mm, 2%/2 mm, 2%/1 mm and 1%/1 mm were recorded. Results There were significant differences in the γ pass rates of treatment plans obtained by the three dose verification systems under different evaluation criteria, but there were no significant differences in the γ pass rates obtained by SRS and PD validation at 3%/2 mm and 2%/2 mm evaluation criteria (all P>0.05); and there were no significant differences in the γ pass rates obtained by Arc and PD validation at 3%/1 mm, 2%/1 mm and 1% /1 mm ( all P>0.05). In determining whether the treatment plan was feasible, SRS was superior to Arc and PD, and PD was slightly superior to Arc. Conclusion All the three dose verification systems can be used for dose verification of stereotactic treatment plans, among which SRS has obvious advantages in stereotactic treatment plan verification due to its high spatial resolution and can be given priority in clinical application. In addition, the more stringent γ evaluation criteria for SRS dose verification can be 2%/1 mm, and the more stringent γ evaluation criteria for Arc and PD dose verification can be 2%/2 mm or 3%/1 mm.